Phase II trial of irinotecan and cisplatin combination as first-line chemotherapy in patients with advanced esophageal squamous-cell carcinoma: An interim report

被引:1
作者
Zhang, X.
Shen, L.
Li, J.
Li, Y.
Zhou, J.
Lu, Z.
Lu, M.
机构
[1] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing 100871, Peoples R China
[2] Peking Univ, Canc Hosp, Dept Gastrointestinal Oncol, Beijing 100871, Peoples R China
关键词
D O I
10.1200/jco.2011.29.4_suppl.137
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
137
引用
收藏
页数:1
相关论文
共 50 条
[11]   Apatinib and irinotecan combination treatment in first-line chemotherapy refractory esophageal squamous cell carcinoma: A phase I dose escalation study [J].
Jia, J. ;
Yu, J. ;
Sun, Z. ;
Yang, Y. ;
Liu, C. ;
Xiao, Y. ;
Zhang, X. .
ANNALS OF ONCOLOGY, 2017, 28
[12]   Phase II trial of paclitaxel and cisplatin combination given biweekly as first-line chemotherapy in patients with advanced or metastatic squamous cell carcinoma of esophagus from a single center in China. [J].
Zhou, Y. ;
Huang, J. ;
Yang, L. ;
Cai, G. R. ;
Xu, H. B. ;
Wang, W. J. ;
Shi, K. Y. ;
Sun, Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[13]   Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer [J].
Sugiyama, T ;
Yakushiji, M ;
Noda, K ;
Ikeda, M ;
Kudoh, R ;
Yajima, A ;
Tomoda, Y ;
Terashima, Y ;
Takeuchi, S ;
Hiura, M ;
Saji, F ;
Takahashi, T ;
Umesaki, N ;
Sato, S ;
Hatae, M ;
Ohashi, Y .
ONCOLOGY, 2000, 58 (01) :31-37
[14]   Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma - A phase II trial [J].
Baur, M ;
Kienzer, HR ;
Schweiger, J ;
DeSantis, M ;
Gerber, E ;
Pont, J ;
Hudec, M ;
Schratter-Sehn, AU ;
Wicke, W ;
Dittrich, C .
CANCER, 2002, 94 (11) :2953-2958
[15]   First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study [J].
Li, Jin ;
Chen, Zhendong ;
Bai, Yuxian ;
Liu, Bo ;
Li, Qingshan ;
Zhang, Jingdong ;
Zhou, Jun ;
Deng, Ting ;
Zhou, Fuyou ;
Gao, Shegan ;
Yang, Shujun ;
Ye, Feng ;
Chen, Long ;
Bai, Wei ;
Yin, Xianli ;
Cang, Shundong ;
Liu, Lianke ;
Pan, Yueyin ;
Luo, Hui ;
Ji, Yanxia ;
Zhang, Zhen ;
Wang, Jufeng ;
Yang, Quanliang ;
Li, Na ;
Huang, Rong ;
Qu, Chenglin ;
Ni, Jing ;
Wang, Bo ;
Xu, Yan ;
Hu, Jin ;
Shi, Qingmei ;
Yang, Jason .
NATURE MEDICINE, 2024, 30 (03) :740-748
[16]   First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study [J].
Jin Li ;
Zhendong Chen ;
Yuxian Bai ;
Bo Liu ;
Qingshan Li ;
Jingdong Zhang ;
Jun Zhou ;
Ting Deng ;
Fuyou Zhou ;
Shegan Gao ;
Shujun Yang ;
Feng Ye ;
Long Chen ;
Wei Bai ;
Xianli Yin ;
Shundong Cang ;
Lianke Liu ;
Yueyin Pan ;
Hui Luo ;
Yanxia Ji ;
Zhen Zhang ;
Jufeng Wang ;
Quanliang Yang ;
Na Li ;
Rong Huang ;
Chenglin Qu ;
Jing Ni ;
Bo Wang ;
Yan Xu ;
Jin Hu ;
Qingmei Shi ;
Jason Yang .
Nature Medicine, 2024, 30 :740-748
[17]   Phase II trial of cisplatin and Gemcitabine in advanced squamous-cell carcinoma of the head and neck [J].
Hitt, R ;
Castellano, D ;
Hidalgo, M ;
García-Carbonero, R ;
Peña, M ;
Brandariz, A ;
Millán, JM ;
Vincent, JJA ;
Cortés-Funes, H .
ANNALS OF ONCOLOGY, 1998, 9 (12) :1347-1349
[18]   CISPLATIN AND IFOSFAMIDE IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX - A PHASE-II TRIAL [J].
CERVELLINO, JC ;
ARAUJO, CE ;
SANCHEZ, O ;
MILES, H ;
NISHIHAMA, A .
ACTA ONCOLOGICA, 1995, 34 (02) :257-259
[19]   Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma [J].
Liu, Shixian ;
Dou, Lei ;
Wang, Kaixuan ;
Shi, Zhao ;
Wang, Ruixue ;
Zhu, Xiaohong ;
Song, Zehua ;
Li, Shunping .
FRONTIERS IN ONCOLOGY, 2022, 12
[20]   Phase II study of irinotecan in combination with capecitabine as a first-line chemotherapy in Asian patients with inoperable hepatocellular carcinoma [J].
Mok, Tony ;
Yang, Tsai-Shen ;
Chao, Yee ;
Wang, Cheng-Hsu ;
Liu, Mei-Ching ;
Kang, Yoon Koo ;
Kang, Won Ki ;
Kim, Jun Suk ;
Wang, Yajie ;
Leung, Thomas .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2009, 5 (02) :95-100